In the HALT-C Trial, a clinical trial with strict patient inclusion criteria, the PEB algorithm improved the sensitivity of AFP by 16.7% compared to the standard thresholding approach (77.1% vs 60.4%) when the screening-level false positive rate was set to 10% and all positive screens in HCC cases were considered to be true positive screens. This evidence concerns the gene AFP and hepatocellular carcinoma.